EGFR and cancer: This novel mechanism of action for targeting tumor cells, together with the other pleiotropic effects of iPA on cancer growth such as angiogenesis inhibition [19] and immune anti-tumor responses stimulation mediated by NK-T [20], radio sensitization effects [21], and the lack of cytotoxicity on noncancerous cells, open the way to new drugs targeting RTKs; iPA alone or in combination with other anti-EGFR therapies can provide a rationale for a more favorable targeted therapy in GBM treatment.